2026-04-11T09:44:47Z https://pub.unibl.org/oai

oai:pub.unibl.org:40912 2024-06-12T14:24:19Z

FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud /unibl/author/JS Smolen /unibl/author/JY Choe /unibl/author/Nenad Prodanović /unibl/author/I Staykov /unibl/author/E Dokoupilova /unibl/author/A Baranauskaite /unibl/author/R Yatsyshyn /unibl/author/M Mekić /unibl/author/W Porawska /unibl/author/H Ciferska /unibl/author/K Jedrichovicz-Rosiak /unibl/author/A Zelinska /unibl/author/Z Lee /unibl/author/YH Rho 2016 Academic Article text 10 10 /unibl/sci/idNaucniRad:25131 ANNALS OF THE RHEUMATIC DISEASES 0003-4967 ANNALS OF THE RHEUMATIC DISEASES 0003-4967 J. Smolen, J. Choe, N. Prodanović, I. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, Z. Lee, Y. Rho, FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016 https://pub.unibl.org/s/cir/item/40912